论文部分内容阅读
Traxanox系benzopyranopyridine的诱导体,一般认为其作用机制与色甘酸二钠(DSCG)相似,可抑制Ⅰ型变态反应中产生的组胺或慢反应物质等化学介质的游离作用,但与DSCG不同之处为可口服。此药不仅对IgE且对和IgG有关的变态反应也有抑制作用,据称对Ⅲ、Ⅳ型变态反应亦有抑制作用。作者对常年性变应性鼻炎患者19例进行了疗效观察。19例中男7例、女12例。年龄14～53岁,平均27.9岁。主要抗原为屋尘及螨共16例,每日给药360mg,试验期间停用其他妨碍判定疗效的药物。鼻部症状改善情况根据患者填写
Traxanox is an inducer of benzopyranopyridine. Its mechanism of action is generally considered to be similar to that of cetuximab (DSCG). It inhibits the dissociation of chemical mediators such as histamine or slow reacting substances produced in type I allergic reactions, but differs from DSCG For oral The drug inhibits not only IgE but also IgG-related allergies, and is said to have an inhibitory effect on type III and IV allergies. The author of perennial allergic rhinitis in 19 patients were observed. There were 7 males and 12 females in 19 cases. Aged 14 to 53 years old, with an average of 27.9 years old. The main antigens were house dust and mites in total of 16 cases. 360mg was administered daily, and other drugs that prevented the determination of efficacy were discontinued during the trial. Improve the nasal symptoms fill in patients